Evidence map›Paper›PMID 41901710›Full record

ArticlePathogens (Basel, Switzerland)2026

Dynamics of Interleukin-9 Producing Lymphocytes in

Wiebke Hartmann, Lennart Heepmann, Lara Linnemann, Paula Licona-Limon, Florent Colomb, Tania Frangova, Henry J McSorley, Minka Breloer

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wiebke HartmannHelminth Immunology, Section Interface, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.ORCID 0000-0002-4998-0586
Lennart HeepmannHelminth Immunology, Section Interface, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Lara LinnemannHelminth Immunology, Section Interface, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.ORCID 0000-0003-4963-2888
Paula Licona-LimonDepartamento de Biología Celular y del Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Florent ColombFaculty of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Tania FrangovaFaculty of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Henry J McSorleyFaculty of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Minka BreloerHelminth Immunology, Section Interface, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.ORCID 0000-0001-6199-4908

Funding

Deutsche Forschungsgemeinschaft DFG BR 3754/10-1 and BR 3754/6-1Wellcome Investigator award 221914/Z/20/Z
6 · The paper itself

Abstract

Helminths infect a quarter of the human population and are controlled in the frame of a canonical type-2 immune response. Interleukin-9 is a cytokine with pleiotropic functions during type-2 immunity that can be produced by many different cells. Accumulating evidence suggest that IL-9 is of particular relevance in controlling intestinal helminth infections. Using mice infected with the parasitic nematode

Indexed as

Interleukin-9LymphocytesStrongyloides rattiStrongyloidiasisAnimalsCD4-Positive T-LymphocytesDisease Models, AnimalImmunity, InnateInterleukin-33Mast CellsMiceInterleukin-33Interleukin-9CD4+ T cellsIL-9ILC2immunosuppressionStrongyloides

Identifiers

PMID41901710
PMCPMC13029138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.